Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial diseas...
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI
- Conditions
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Portola Pharmaceuticals
- Target Recruit Count
- 652
- Registration Number
- NCT00751231
- Locations
- 🇵🇱
Portola Investigational Site, Warsaw, Poland
Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)
- Conditions
- Interventions
- First Posted Date
- 2008-08-05
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
- Target Recruit Count
- 90
- Registration Number
- NCT00728156
- Locations
- 🇬🇧
Newcastle Diabetes Centre, Newcastle General Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom
🇬🇧Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom
Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients Undergoing Coronary Artery Bypass Surgery.
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2008-07-30
- Lead Sponsor
- Catharina Ziekenhuis Eindhoven
- Target Recruit Count
- 135
- Registration Number
- NCT00724880
CASTLE (Clopidogrel And Serum Troponin Level Elevation)
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 155
- Registration Number
- NCT00716924
- Locations
- 🇲🇽
Sanofi aventis administrative office, Mexico, Mexico
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
- Conditions
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2013-05-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 9326
- Registration Number
- NCT00699998
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sunderland, United Kingdom
Effect of Different Dosing Regimens of Clopidogrel Before Elective Percutaneous Coronary Intervention (PCI) on Platelet Function
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2012-08-21
- Lead Sponsor
- Hopital du Sacre-Coeur de Montreal
- Target Recruit Count
- 120
- Registration Number
- NCT00693069
- Locations
- 🇨🇦
Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 102
- Registration Number
- NCT00687076
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)
- Conditions
- Interventions
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT00684203
Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Deutsches Herzzentrum Muenchen
- Target Recruit Count
- 4005
- Registration Number
- NCT00661206
- Locations
- 🇺🇸
University of Florida, Health Science Center - Jacksonville, Jacksonville, Florida, United States
🇦🇱Spitali Gjerman, Tirana, Albania
🇦🇹Krankenanstalt Rudolfstiftung, Wien, Austria
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety
- Conditions
- Interventions
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2011-06-16
- Lead Sponsor
- Accumetrics, Inc.
- Target Recruit Count
- 2800
- Registration Number
- NCT00645918
- Locations
- 🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States
🇺🇸The Miriam Hospital, Providence, Rhode Island, United States
🇺🇸Black Hills Clinical Research Center, Rapid City, South Dakota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.